The global Nuclear Medicine Market is poised for remarkable growth, with its market size projected to increase from USD 11.1 billion in 2023 to an estimated USD 38.8 billion by 2032, representing a compound annual growth rate (CAGR) of 15% during the forecast period from 2024 to 2032.

Get Free Sample Report on Nuclear Medicine Market

https://www.snsinsider.com/sample-request/2243

This rapid growth underscores the expanding role of nuclear medicine in diagnostics, therapy, and personalized treatment. As healthcare systems worldwide increasingly adopt precision medicine approaches, nuclear medicine technologies are emerging as key enablers of earlier diagnosis and targeted therapies, particularly in oncology, cardiology, and neurology.

Market Growth Drivers

The expansion of the nuclear medicine market is fueled by several compelling factors:

  • Rising Prevalence of Chronic Diseases: Increasing incidences of cancer, cardiovascular diseases, and neurological disorders are driving demand for advanced imaging and targeted radiopharmaceuticals.
  • Advancements in Radiopharmaceuticals: Innovations in radiotracers and targeted isotopes are enhancing the efficacy and safety of nuclear medicine procedures, fueling wider adoption.
  • Growing Geriatric Population: Aging populations worldwide are more susceptible to chronic diseases, thereby increasing the need for diagnostic and therapeutic nuclear medicine interventions.
  • Supportive Government Initiatives: Public and private investments in medical imaging infrastructure, along with favorable reimbursement policies, are accelerating market growth.
  • Integration of AI and Hybrid Imaging: The combination of nuclear imaging with AI-powered diagnostic tools and hybrid modalities like PET/CT and SPECT/CT is enabling more precise and efficient diagnosis.

Key Market Segments:

By Product

  • Diagnostics
  • SPECT
    • TC-99m
    • TL-201
    • GA-67
    • I-123
    • Others
  • PET
    • F-18
    • SR-82/RB-82
    • PYLARIFY (piflufolastat F 18)
    • Illuccix (gallium Ga 68 gozetotide)
    • Others
  • Therapeutics
    • Alpha Emitters
      • RA-223
      • Others
    • Beta Emitters
      • I-131
      • Y-90
      • SM-153
      • Re-186
      • Lu-177
      • Others
    • Brachytherapy
      • Cesium-131
      • Iodine-125
      • Palladium-103
      • Iridium-192
      • Others

By Application

  • Cardiology
    • SPECT
    • PET
    • Therapeutic Applications
  • Neurology
  • Oncology
  • Thyroid
    • SPECT
    • Therapeutic Applications
  • Lymphoma
  • Bone Metastasis
    • SPECT
    • Therapeutic Applications
  • Endocrine Tumor
  • Pulmonary Scans
  • Urology
  • Other

By End-use

  • Hospitals
  • Diagnostic Centers
  • Others

Key Players

Key Service Providers/Manufacturers

  • GE HealthCare (Discovery NM/CT 670, Discovery PET/CT 710)
  • Siemens Healthineers (Biograph Vision PET/CT, Symbia Intevo SPECT/CT)
  • Philips Healthcare (Vereos Digital PET/CT, BrightView SPECT)
  • Canon Medical Systems Corporation (Celesteion PET/CT, Aquilion ONE/GENESIS Edition)
  • Lantheus Medical Imaging, Inc. (DEFINITY, TechneLite)
  • Bracco Imaging S.p.A(MultiHance, CardioGen-82)
  • Cardinal Health(Lymphoseek, Zevalin)
  • Curium (Sodium Iodide I-131, Thallium-201)
  • Eckert & Ziegler (GalliaPharm, Yttriga)
  • Nordion (Canada), Inc. (Cobalt-60, Molybdenum-99)
  • NTP Radioisotopes SOC Ltd. (Fluorodeoxyglucose (FDG), Iodine-131)
  • Advanced Accelerator Applications(a Novartis company) (Lutathera, NETSPOT)
  • Jubilant Life Sciences Ltd. (Iodine-131, Molybdenum-99)
  • Eczacıbaşı-Monrol (FDG, Gallium-68)
  • Australian Nuclear Science and Technology Organisation (ANSTO) (Technetium-99m, Molybdenum-99)
  • Shine Technologies (Molybdenum-99, Lutetium-177)
  • Telix Pharmaceuticals, Inc. (Illuccix, TLX591)

Challenges and Opportunities

While the outlook for nuclear medicine is highly positive, the industry faces several challenges:

  • Short Half-Life of Isotopes: Many radiopharmaceuticals have short shelf lives, requiring efficient logistics and supply chain management.
  • Regulatory Hurdles: Nuclear medicine is subject to strict regulatory frameworks, which can slow down approval processes for new treatments.
  • Limited Access in Emerging Markets: Despite growing interest, many regions still lack the infrastructure and trained personnel to effectively deploy nuclear medicine technologies.

However, these challenges are accompanied by significant opportunities. Advancements in isotope production, AI integration, and theranostic applications are expected to unlock new growth avenues. Additionally, increasing collaboration between academia, government, and private enterprises is fostering innovation and expanding access.

Make Enquiry about Nuclear Medicine Market

https://www.snsinsider.com/enquiry/2243

Future Outlook

The future of nuclear medicine is being shaped by innovation, precision, and accessibility. As personalized medicine becomes the gold standard in healthcare, nuclear imaging and therapy will play a central role in delivering tailored treatments that improve patient outcomes and reduce healthcare costs.

With a projected market value of USD 38.8 billion by 2032, the nuclear medicine sector is on track to become a foundational pillar of modern diagnostics and therapeutics. Companies that invest in R&D, streamline logistics, and expand globally will be at the forefront of this fast-evolving industry.

 About US

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:

Jagney Dave - Vice President of Client Engagement

Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)